This document discusses glaucoma, including what causes it, types of glaucoma, and treatments. Glaucoma is a disease that causes damage to the eye due to increased pressure from fluid inside the eye. There are two main types: open angle glaucoma, the most common type where fluid drainage is blocked, and angle closure glaucoma where the drain becomes too narrow. Treatments aim to lower pressure by decreasing fluid production or increasing outflow, through drugs like prostaglandin analogues, beta blockers, alpha agonists, and carbonic anhydrase inhibitors. Miotic drugs may also be used but have more side effects. Treatment depends on the type of glaucoma and may involve multiple drug
2. GLAUCOMA
GLAUCOMA IS A DISEASE THAT CAUSES DAMAGE
TO THE EYE.
THIS DISEASE HAPPENS BECAUSE OF INCREASED
PRESSURE IN THE EYE. THE PRESSURE CAUSES
DAMAGE TO THE OPTIC NERVE.
6. WHAT CAUSES GLAUCOMA ?
1. The clear fluid inside the eye is produced by the ciliary body
2. This fluid, known as aqueous humour, flows behind the iris. The
aqueous humour fills the anterior chamber, a space between back
of cornea and front of iris
3. The fluid exists the eye through the structure known as the drainage
angle(Schlemms Canal), which is formed inside the anterior the
anterior chamber between iris and cornea.
4. The aqueous filters through this angle and through the sclera or
white part of the eye and then joins with the network of veins
outside the eye
5. Any disruption of this outflow of aqueous including form certain
eye injuries can result in an increase in Intra Ocular pressure
(I.O.P.) 6
8. TYPES OF GLAUCOMA
A. Open Angle (Wide angle, Chronic simple)
Glaucoma
B. Angle Closure (Narrow angle, Acute congestive)
Glaucoma
8
9. A. OPEN ANGLE (WIDE ANGLE, CHRONIC
SIMPLE) GLAUCOMA
It is the most common type.
The drain structure in the eye it is called
trabecular meshwork looks normal, but the
fluid dosent flow out like it should
9
10. B. ANGLE CLOSURE (NARROW ANGLE, ACUTE
CONGESTIVE) GLAUCOMA
It is less common type
Eye doesn't drain right because the drain
space between iris and cornea become too
narrow
This can cause a sudden buildup of pressure
in our eye
10
15. ALPHA ADRENERGIC AGONIST
Adrenergic Alpha 1:- vasoconstriction of ciliary muscles
Adrenergic Alpha 2:- Reduce action of ciliary epithelium
activity
Examples : Dipivefrine, Apraclonidine, Brimonidine.
Dipivefrine :- It is a prodrug of ADR; penetrated cornea and
is hydrolyzed by the esterase present there into ADR which
lowers IOT by augmenting uveoscleral outflow.
Apraclonidine :- it decreases aqueous production by
primary alpha 2 and subsidiary alpha 1 action on ciliary
body
Brimonidine :- it is more Alpha 2 selective and more lipofilic
than Apraclonidine. It lowers I.O.T. by reducing aqueous
production and by increasing Uveosclereal flow
15
17. BETA ADRENERGIC BLOCKERS
Beta 2 adrenoreceptors located on ciliary epithelium enhance
aqueous secretion by a increased cAMP and they are blocked by
Timolol / Betaxolol.
Beta blockers reduce the I.O.P by blockade of sympathetic nerve
ending in the ciliary epithelium causing a fall in aqueous humor
production
Timolol :- it is the prototype of ocular beta blockers it is non
selective (硫1 + 硫2)
Betaxolol :- it is a 硫1 selective blocker offering the advantage of
less bronchopulmonary and probably less cardiac central and
metabolic side effects. However it is less efficious in lowering I.O.T.
than timolol because, ocular beta receptors are predominantly of
the 硫2 subtype.
Most opthmalogist prefer to start with betaxolol and change over
to timolol if there is insufficient control or local intolerance to
betaxolol 17
18. CONTINUED
Side effects are
1. Ocular side effect
Stinging(smoke stinging/burning sensation),
redness, dryness of eye, corneal
hypoesthesia(decrease in sensation), blur
vision.
2. Systemic side effect
Bronchospasm, bradycardia ( decrease heart
rate)
18
19. PROSTAGLANDIN ANALOGUE
It act by increasing Uveoscleral outflow, possibly by
increasing permeability of tissues in ciliary muscles or by
an action on episcleral vessels(clear layer on top of the
white part of eye, outside which conjunctiva is present.
Example : Latanoprost, Travoprost, Bimatoprost.
Latanoprost
It is the 1st choice drug for open angle
glaucoma because of
Good Efficacy (maximum response of drug)
Once daily Application
Absence of systemic complication
Bimatoprost
It is equally effective as Latanoprost how ever
it has more side effects
19
21. CARBONIC ANHYDRASE INHIBITORS
MOA
It work by inhibiting carbonic anhydrase
(isoenzyme II), which is found in ciliary body
epithelium. This reduces the formation of
bicarbonate ions, which reduces fluid transport,
reducing fluid I.O.P
Example Acetazolamide, Dorzolamide
Acetazolamide
It is given Orally
Dorzolamide
It is given Topically (external application of the
drug on the surface i.e. skin or mucous
membrane of eye for localized action) 21
22. MIOTICS
These reduce eye pressure by increasing the
drainage of intraocular fluid through the trabecular
meshwork i.e by increasing ciliary muscle tone
These drugs especially Pilocarpine previously were
the standard antiglaucoma drug
However, because of several drawbacks, they are
used only as THE LAST OPTION.
22
24. 24
Start monotherapy with Latanoprost / another PG Analogue / Topical beta blocker
If target I.O.T. is not attained,
Either change over to the alternative drug or use both above concurrently (at the same time) .
When there are contraindication to PG analogues and/or beta blockers or to
supplement their action
Brimonidine / Dorzolamide (occasionally Dipivefrine) are used
Topical miotics and Acetazolamide are added (used as the last Option)
25. ANGLE CLOSURE
25
Vigorous therapy employing several measures to reduce I.O.T.
Hypertonic mannitol
Acetazolamide
Miotic
Topical beta blockers
Apraclonidine 1% (/Latanoprost 0.005%)
NOTE
These drugs are used only to terminate the attack of angle closure glaucoma
Definitive treatment is surgical or laser peripheral iridotomy (standard first-line
treatment)
These may be treated with these drugs for long periods, but often surgery or laser
therapy is ultimately required.